Table 5

 Cumulative major outcomes, quality adjusted life years lost, and costs expected over 10 years, the incremental cost per outcome for each screening strategy, and the average cost per outcome (compared to no screening) for each assumption about pelvic inflammatory disease (PID) progression: PID = 30%

Total MOTotal QALYs lostTotal cost (£)Incremental cost (£)/MOAIncremental cost (£)/QALY gainedAverage cost (£)/MOAAverage cost (£)/QALY gained
MO, major outcome; MOA, major outcomes averted. Values in the table are rounded for presentation. QALY, quality adjusted life years; All costs and effects are discounted at 3.5%. Results are presented in rank order of total costs, which include costs of infection, complications, and programme costs. Dominated means that the MOA or QALYs gained is less than the non-dominated strategy above it in the table.
Baseline, noscreening3529156709 068––––
Strategy 1 <20221692796 042661364661364
Strategy 2 <20187875974 85452910 4021613283
Strategy 3 <201676661 008 67816838451623338
Strategy 1 <251799751 110 924DominatedDominated2324960
Strategy 1 <301641701 466 41313 279Dominated4018799
Strategy 2 <251397551 600 01554653 3174188834
Strategy 3 <251195461 682 28040789614178845
Strategy 1 <351574681 842 956DominatedDominated58012 987
Strategy 1 <401508662 213 265DominatedDominated74416 829
Strategy 2 <301200482 277 375DominatedDominated67314 589
Strategy 3 <301018412 419 1814181149 93068114 877
Strategy 2 <351138472 991 631DominatedDominated95521 068
Strategy 3 <35909383 163 0116835238 07693720 783
Strategy 2 <401071463 696 199DominatedDominated121527 228
Strategy 3 <40852373 921 64513 304714 049120026 966